Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2013

View Archived Issues

Researchers publish report on chemically attenuated low-dose parasite-containing antimalaria vaccine

New renin inhibitors for the treatment of hypertension revealed by Daiichi Sankyo

Researchers in Poland present new caspase-3 and -7 activators

Plasma markers correlate with obstructive sleep apnea syndrome severity

Champions Oncology and Teva sign drug development agreement

Tetraphase describes novel tetracycline antibacterials

Evotec AG and Harvard Stem Cell Institute form CureMN collaboration

Mount Sinai grants Plexcera license to develop rhAC-based treatments

Circassia reports phase II findings for house dust mite allergy treatment

GlaxoSmithKline receives FDA priority review for dabrafenib/trametinib sNDAs

FDA grants breakthrough therapy designation to ofatumumab for previously untreated CLL

EMA grants orphan drug status to GMI-1070 in sickle cell disease

Data from phase II study of brincidofovir for preventing adenovirus disease presented

Cubist Pharmaceuticals completes acquisition of Trius Therapeutics

Ganymed obtains CE Mark for Claudetect 18.2 test

Bullet Biotechnology updates on financing and product development

Taiho Pharmaceutical divulges new Aurora kinase A inhibitors

Regeneron describes human monoclonal IgG4 antibodies targeting big ET-1

FDA lifts clinical hold on Pluristem's study of PLX-PAD for intermittent claudication

Adaptive Biotechnologies receives SBIR grant

Arbor Pharmaceuticals to market and sell Edarbi and Edarbyclor in U.S.

Swissmedic accepts for review ceftobiprole MAA for pneumonia

Astellas Pharma reports discovery of dual 5-HT2B/5-HT7 receptor antagonists for IBS

Alemtuzumab approved for multiple sclerosis in the E.U.

Tolvaptan approved in Japan to treat fluid retention in patients with hepatic cirrhosis

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...